文献速递乳腺癌

HER2阳性乳腺癌中药物耐受持留细胞的起源与脆弱性

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer.
PubMed 文献 · Cancer Discov · 2022-01-01

该研究探讨HER2阳性乳腺癌中药物耐受持留细胞(DTP)的起源与脆弱性。HER2酪氨酸激酶抑制剂(TKI)可诱导出管腔样或间质样转录组的DTP; lentiviral barcoding与单细胞RNA测序显示HER2阳性乳腺癌细胞以G0样表达签名随机循环进入「pre-DTP」状态,该状态富集滞育和/或衰老基因。轨迹分析与细胞分选表明pre-DTP在HER2 TKI暴露后优先产生DTP;HER2阳性乳腺肿瘤中存在类似转录组的细胞且与TKI反应差相关。生化实验提示管腔样DTP通过雌激素受体依赖的SGK3诱导存活,导致PI3K/AKT/mTORC1通路重塑以实现不依赖AKT的mTORC1激活。

要点

  • HER2 TKI可诱导出管腔样或间质样转录组的药物耐受持留细胞(DTP)。
  • pre-DTP以G0样表达签名随机产生并富集滞育和/或衰老基因,TKI暴露后优先生成DTP。
  • 管腔样DTP通过雌激素受体依赖的SGK3诱导重塑PI3K/AKT/mTORC1通路实现不依赖AKT的mTORC1激活。

核心结论

  • HER2 TKI-DTP起源于随机产生的「pre-DTP」细胞,TKI暴露后这些细胞进入两种不同的转录程序。
  • 该结果为了解DTP起源及潜在治疗脆弱性提供了新见解。

研究设计与样本

  • 研究采用HER2阳性乳腺癌细胞模型,结合慢病毒条形码与单细胞RNA测序、轨迹分析、细胞分选及生化实验。

主要发现

  • HER2 TKI诱导的DTP具有管腔样或间质样转录组。
  • HER2阳性乳腺癌细胞以G0样表达签名随机循环进入pre-DTP状态,该状态富集滞育和/或衰老基因。
  • 轨迹分析与细胞分选显示pre-DTP在HER2 TKI暴露后优先产生DTP。
  • HER2阳性乳腺肿瘤中存在转录组相似的细胞,且与TKI反应差相关。
  • 管腔样DTP通过雌激素受体依赖的SGK3诱导存活,导致PI3K/AKT/mTORC1通路重塑以实现不依赖AKT的mTORC1激活。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Resistance to targeted therapies is an important clinical problem in HER2-positive (HER2+) breast cancer. "Drug-tolerant persisters" (DTP), a subpopulation of cancer cells that survive via reversible, nongenetic mechanisms, are implicated in resistance to tyrosine kinase inhibitors (TKI) in other malignancies, but DTPs following HER2 TKI exposure have not been well characterized. We found that HER2 TKIs evoke DTPs with a luminal-like or a mesenchymal-like transcriptome. Lentiviral barcoding/single-cell RNA sequencing reveals that HER2+ breast cancer cells cycle stochastically through a "pre-DTP" state, characterized by a G0-like expression signature and enriched for diapause and/or senescence genes. Trajectory analysis/cell sorting shows that pre-DTPs preferentially yield DTPs upon HER2 TKI exposure. Cells with similar transcriptomes are present in HER2+ breast tumors and are associated with poor TKI response. Finally, biochemical experiments indicate that luminal-like DTPs survive via estrogen receptor-dependent induction of SGK3, leading to rewiring of the PI3K/AKT/mTORC1 pathway to enable AKT-independent mTORC1 activation. SIGNIFICANCE: DTPs are implicated in resistance to anticancer therapies, but their ontogeny and vulnerabilities remain unclear. We find that HER2 TKI-DTPs emerge from stochastically arising primed cells ("pre-DTPs") that engage either of two distinct transcriptional programs upon TKI exposure. Our results provide new insights into DTP ontogeny and potential therapeutic vulnerabilities. This article is highlighted in the In This Issue feature, p. 873.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Chang CA, Jen J, Jiang S, et al. Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer. Cancer Discov. 2022. PMID: 34911733. doi:10.1158/2159-8290.CD-20-1265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。